Skip to main content
OTCMKTS:ACUS

Acusphere Competitors

$0.05
+0.01 (+32.35 %)
(As of 05/17/2021 11:38 AM ET)
Add
Compare
Today's Range
$0.04
$0.05
50-Day Range
$0.03
$0.05
52-Week Range
$0.01
$0.06
Volume14,030 shs
Average Volume19,977 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-0.25

Competitors

Acusphere (OTCMKTS:ACUS) Vs. AFFY, ARYX, AHROQ, CBPI, CDSG, and CHHE

Should you be buying ACUS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Acusphere, including Affymax (AFFY), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG), and China Health Industries (CHHE).

Affymax (OTCMKTS:AFFY) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares Affymax and Acusphere's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AffymaxN/AN/AN/A
AcusphereN/AN/AN/A

Valuation & Earnings

This table compares Affymax and Acusphere's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AffymaxN/AN/AN/AN/AN/A
AcusphereN/AN/AN/AN/AN/A

Risk & Volatility

Affymax has a beta of 2.77, meaning that its share price is 177% more volatile than the S&P 500. Comparatively, Acusphere has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Affymax and Acusphere, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Affymax0000N/A
Acusphere0000N/A

Summary

Affymax beats Acusphere on 1 of the 1 factors compared between the two stocks.

ARYx Therapeutics (OTCMKTS:ARYX) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Profitability

This table compares ARYx Therapeutics and Acusphere's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ARYx TherapeuticsN/AN/AN/A
AcusphereN/AN/AN/A

Valuation & Earnings

This table compares ARYx Therapeutics and Acusphere's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ARYx TherapeuticsN/AN/AN/AN/AN/A
AcusphereN/AN/AN/AN/AN/A

Risk & Volatility

ARYx Therapeutics has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500. Comparatively, Acusphere has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ARYx Therapeutics and Acusphere, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ARYx Therapeutics0000N/A
Acusphere0000N/A

Summary

Acusphere beats ARYx Therapeutics on 1 of the 1 factors compared between the two stocks.

AtheroNova (OTCMKTS:AHROQ) and Acusphere (OTCMKTS:ACUS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Risk & Volatility

AtheroNova has a beta of -8.71, meaning that its share price is 971% less volatile than the S&P 500. Comparatively, Acusphere has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for AtheroNova and Acusphere, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtheroNova0000N/A
Acusphere0000N/A

Profitability

This table compares AtheroNova and Acusphere's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtheroNovaN/AN/AN/A
AcusphereN/AN/AN/A

Valuation & Earnings

This table compares AtheroNova and Acusphere's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtheroNovaN/AN/AN/AN/AN/A
AcusphereN/AN/AN/AN/AN/A

Summary

Acusphere beats AtheroNova on 1 of the 1 factors compared between the two stocks.

Acusphere (OTCMKTS:ACUS) and China Botanic Pharmaceutical (OTCMKTS:CBPI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Acusphere has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, China Botanic Pharmaceutical has a beta of 17.09, meaning that its stock price is 1,609% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Acusphere and China Botanic Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
China Botanic Pharmaceutical0000N/A

Profitability

This table compares Acusphere and China Botanic Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/A

Valuation and Earnings

This table compares Acusphere and China Botanic Pharmaceutical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
China Botanic PharmaceuticalN/AN/AN/AN/AN/A

Summary

China Botanic Pharmaceutical beats Acusphere on 1 of the 1 factors compared between the two stocks.

Acusphere (OTCMKTS:ACUS) and China Dongsheng International (OTCMKTS:CDSG) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Acusphere has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, China Dongsheng International has a beta of 13.38, meaning that its stock price is 1,238% more volatile than the S&P 500.

Profitability

This table compares Acusphere and China Dongsheng International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
China Dongsheng InternationalN/AN/AN/A

Valuation and Earnings

This table compares Acusphere and China Dongsheng International's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
China Dongsheng InternationalN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Acusphere and China Dongsheng International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
China Dongsheng International0000N/A

Summary

China Dongsheng International beats Acusphere on 1 of the 1 factors compared between the two stocks.

Acusphere (OTCMKTS:ACUS) and China Health Industries (OTCMKTS:CHHE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Risk & Volatility

Acusphere has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500. Comparatively, China Health Industries has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.

Profitability

This table compares Acusphere and China Health Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AcusphereN/AN/AN/A
China Health Industries34.11%8.60%7.05%

Earnings & Valuation

This table compares Acusphere and China Health Industries' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AcusphereN/AN/AN/AN/AN/A
China Health Industries$9.93 millionN/A$3.55 millionN/AN/A

China Health Industries has higher revenue and earnings than Acusphere.

Analyst Recommendations

This is a breakdown of recent ratings for Acusphere and China Health Industries, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acusphere0000N/A
China Health Industries0000N/A

Summary

China Health Industries beats Acusphere on 5 of the 5 factors compared between the two stocks.


Acusphere Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Affymax logo
AFFY
Affymax
0.6$0.08+0.0%$0.00N/A0.00Gap Down
ARYX
ARYx Therapeutics
0.0$0.01+0.7%$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01+0.0%$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.08+6.0%$0.00N/A0.00Gap Down
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.05+19.2%$0.00N/A0.00Gap Down
China Health Industries logo
CHHE
China Health Industries
0.4$0.25+0.0%$0.00$9.93 million4.20Upcoming Earnings
DDXSQ
Diadexus
0.0$0.00+0.0%$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04+0.0%$0.00N/A0.00
FTCY
Global Future City
0.5$0.00+5,000,000.0%$0.00N/A0.00Gap Down
GLSI
Greenwich LifeSciences
2.0$32.89+0.2%$0.00N/A0.00
HRBR
Harbor Diversified
0.0$1.90+10.5%$0.00$263.61 million0.00Gap Up
IPAH
Interpharm
0.2$0.00+0.0%$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00+0.0%$0.00N/A0.00
MBVXQ
MabVax Therapeutics
0.0$0.02+8.7%$0.00N/A0.00Gap Down
MYRX
Myrexis
0.5$0.05+0.0%$0.00N/A0.00Gap Down
NNBP
Nanobac Pharmaceuticals
0.0$0.00+100.0%$0.00N/A0.00Gap Down
PARD
Poniard Pharmaceuticals
0.5$0.09+0.0%$0.00N/A0.00
SGTI
Shengtai Pharmaceutical
0.2$0.02+0.0%$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00+0.0%$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.05+2.2%$0.00$26.09 million0.00Gap Up
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.03+1.9%$0.00N/A0.00
SYNI
Synvista Therapeutics
0.0$0.00+0.0%$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00+0.0%$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.01+3.0%$0.00N/A0.00High Trading Volume
Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.01+0.0%$0.00N/A0.00
This page was last updated on 5/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.